Anti-Aging Drug Raising Brain Damage Concerns

white pills spilling from prescription bottles — Photo: Steve Heap / Shutterstock

A drug combination that longevity researchers have been quietly self-experimenting with for years just caused part of the brain to vanish in mice — and the field has some explaining to do.

Story Snapshot

A new study published in the Proceedings of the National Academy of Sciences found that dasatinib and quercetin caused significant brain damage in mice, including destruction of the corpus callosum — the brain’s primary communication bridge between hemispheres.
The damage occurred in both young and aged mice, suggesting the harm is not limited to older, more vulnerable animals.
Earlier research had shown the same drug combination could preserve cognitive function and reduce brain inflammation in Alzheimer’s disease mouse models.
Human pilot data describe the combination as well-tolerated, but no long-term human brain imaging data exists to confirm safety.

The Drug Combo That Became a Longevity Darling

Dasatinib is a leukemia drug. Quercetin is a plant compound found in onions and apples. Together, they became the flagship treatment in a class of therapies called senolytics — drugs designed to kill “zombie cells,” the senescent cells that accumulate with age, stop dividing, and pump out inflammatory signals that degrade surrounding tissue. The theory is elegant: clear the zombie cells, slow the aging process. That promise attracted serious scientific attention and a growing number of biohackers willing to dose themselves without waiting for clinical trial results. ^[5]

The combination earned its reputation partly through a 2019 study from Johns Hopkins researchers who found that dasatinib and quercetin eliminated senescent cells in the brain, reduced neuroinflammation by roughly 50 percent, and preserved cognitive function in an Alzheimer’s disease mouse model. ^[1] That result circulated widely in longevity communities and reinforced the idea that this drug pair was not just safe but actively brain-protective. The new University of Connecticut findings published in the Proceedings of the National Academy of Sciences (PNAS) tell a sharply different story.

What the New Mouse Study Actually Found

Researchers treated both young mice aged three to four months and aged mice at twenty-two months with dasatinib and quercetin. Both groups developed significant demyelination — the stripping away of the protective myelin sheath that insulates nerve fibers and allows signals to travel efficiently through the brain. ^[7] Myelin loss is not a minor side effect. It is the same type of damage seen in multiple sclerosis. Without myelin, neurons fire slowly, misfire, or stop communicating altogether.

The corpus callosum, the thick band of nerve fibers connecting the brain’s left and right hemispheres, deteriorated severely enough in treated mice that University of Connecticut researchers described it as having disappeared. ^[5] The corpus callosum handles nearly every coordinated cognitive task a brain performs. Its degradation is associated with cognitive decline, impaired motor control, and in humans, conditions ranging from traumatic brain injury to advanced neurodegeneration. The drug combination also disrupted oligodendrocyte function — the cells responsible for producing and maintaining myelin. ^[7]

Why Earlier Studies Showed the Opposite Result

The contradiction between the 2019 Hopkins findings and the new PNAS data is not as paradoxical as it first appears. The 2019 study used an Alzheimer’s disease mouse model, meaning the animals had pre-existing pathology that senolytic treatment may have partially corrected. ^[1] The new study used healthy mice with no underlying disease. That distinction matters enormously. A drug that reduces harmful senescent cell accumulation in a diseased brain may simultaneously damage the healthy oligodendrocyte population in a normal brain. Senolytics do not discriminate cleanly between dangerous zombie cells and useful aging cells performing necessary functions.

A human pilot study called the STAMINA trial reported that dasatinib and quercetin were well-tolerated in older adults at risk for Alzheimer’s disease, with some cognitive improvement observed in participants with the lowest baseline scores. ^[3] That sounds reassuring, but pilot studies are small, short in duration, and not designed to detect slow-developing structural brain changes. No one has run MRI imaging on human corpus callosum tissue after repeated senolytic dosing cycles over years. The mice in the PNAS study showed damage. The humans in the pilot study showed short-term tolerability. Those are not the same measurement.

What This Means for People Already Taking It

Thousands of people in longevity and biohacking communities have self-administered dasatinib and quercetin in cycles, often following protocols they found online, without physician oversight or imaging follow-up. Dasatinib is a prescription drug approved for cancer treatment, not anti-aging. Quercetin is sold freely as a supplement. The combination is accessible enough that casual use became normalized in certain circles well before the safety profile was understood. The PNAS findings do not prove that humans experience the same white-matter damage seen in mice, but they establish a serious enough signal that continuing without medical supervision and monitoring is a gamble that common sense argues strongly against. ^[8]

Longevity science moves fast and the media tends to amplify breakthroughs while burying complications. The dasatinib and quercetin story is a useful reminder that eliminating cells your body has held onto for decades — even damaged ones — carries consequences that a single promising mouse study cannot fully predict. The field needs longer human trials with neuroimaging endpoints before this combination earns the casual endorsement it has already received. ^[2]